Article Text
Letter
Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?
Statistics from Altmetric.com
Footnotes
Competing interests: BH has received consulting fees/honoraria from Astra-Zeneca and Novartis, and has received research support from Bayer. KB has received consulting fees/honoraria from Bayer, Merck, Sharp & Dohme and Novartis, and has received research support from Aventis, Bayer, Merck, Shorp & Dohme and Novartis. BR has received research support from Merck, Sharp & Dohme, GlaxoSmithKline and Philip Morris USA.
BH and BR contributed equally to this work.